Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    Hepatitis C virus (HCV) is chiefly transmitted by blood-to-blood contact. When the blood of a person with hepatitis C enters the bloodstream of another person,...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1
  • Hepatitis C virus treatment

    The current preferred treatment regimen for HCV infection is a combination of peginterferon alfa (given by injection) plus ribavirin (given orally). Interferons are human proteins that...

    From: HIV treatments directory

    Information level Level 4
  • Treatment for hepatitis C

    Treatments are available for hepatitis C and aim to cure the condition. People with HIV who are newly diagnosed with hepatitis C should consider the pros and...

    From: Booklets

    Information level Level 2

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • German insurers win discounts on Gilead's Sovaldi

    The head of Gilead's German operations told the magazine that discounts from the list price of 60,000 euros (44,867 pounds) per treatment had been negotiated with four of Germany's statutory health insurers but declined to give the size of the discounts.

    26 January 2015 | Yahoo News
  • Merck discontinues Victrelis (boceprevir) voluntarily in the United States

    Merck has decided to voluntarily discontinue the manufacture and distribution of Victrelis in the United States by December 2015.

    21 January 2015 | EATG
  • Gilead and AbbVie take hepatitis C battle to Europe

    Europe is to become the next battleground between Gilead Sciences and AbbVie in their scramble to win share of the fast-growing market for hepatitis C drugs. The companies have been fighting a high-profile price war in the US over a new generation of blockbuster medicines that can cure most people with the virus within weeks. The pair are preparing to open a new front across the Atlantic after European regulators gave AbbVie’s hepatitis C treatment the green light on Friday.

    20 January 2015 | Financial Times (free registration required)
  • The Cynical Connectedness of Gilead's Hepatitis C Pricing and Anti-Diversion Policies

    Gilead has announced both the highest recorded prices ever for its direct acting hepatitis C antiviral, ledipasvir/sofosbuvir (Harvoni), and one of the most stringent anti-diversion programs ever devised. The price, highest in the U.S., comes in at a whopping US$94,000 for a 12-week course of treatment, with slightly lower prices in Europe.

    19 January 2015 | The Body Pro
  • Hepatitis C drug delayed by NHS due to high cost

    The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected with the hepatitis C virus. The move by NHS England is unprecedented, because the NHS rationing body, Nice (the National Institute for Health and Care Excellence) has approved the drug. Nice says sofosbuvir is cost-effective, because it is a cure for people who would otherwise run up huge NHS bills.

    16 January 2015 | The Guardian
  • European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C

    The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 (GT4) chronic hepatitis C patients.

    16 January 2015 | AbbVie press release
  • How Much Could AbbVie Inc. Make Selling Its Hepatitis C Drug This Year?

    AbbVie has issued its guidance for 2015, and that guidance suggests that its newly launched hepatitis C drug cocktail, Viekira Pak, could be a big driver of earnings growth this year. In December, Viekira Pak received FDA approval as a treatment for hepatitis C genotype 1 after delivering compelling functional cure rates in the mid-90% range during clinical trials. That approval was highly anticipated by health care payers desperate for competition in this market, because hepatitis C market share leader Gilead Sciences' two hepatitis C drugs, Sovaldi and Harvoni, carry eye-popping price tags that are translating into billions of additional dollars in health care spending.

    15 January 2015 | The Motley Fool
  • India rejects Gilead's Hepatitis C drug patent request

    India's patent office has rejected an application from U.S.-based Gilead Sciences Inc for its hepatitis C drug Sovaldi, paving the way for local drugmakers to launch cheaper generic versions of the $1,000-a-pill medicine.

    14 January 2015 | Reuters
  • Doctors Question Wider Hepatitis C Screening Despite Cures

    Doctors should resist the urge to screen a wider group of patients for hepatitis C, a group of physicians said today in the British Medical Journal, despite the introduction of new drugs that can cure the liver disease. Expanded screening would flag the disease in people who are unlikely to die from it, leading to unnecessary treatment that may itself be harmful, said the group, including Kenneth Lin, an associate professor at Georgetown University School of Medicine.

    14 January 2015 | Bloomberg
  • US: Prime Therapeutics breaks from competition, strikes deals to prefer both Harvoni, Viekira hepatitis C drugs

    The agreements place both Gilead’s Harvoni® and AbbVie’s Viekira Pak® on Prime’s preferred drug list (formulary), meaning members can more easily get the medicine they need to feel better and live well.

    13 January 2015 | Prime Therapeutics press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.